Biotech · Private company · Raleigh, NC, US
Glycan Therapeutics Corporation
Track this companyFree. Adds Glycan Therapeutics Corporation to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Development of heparan sulfate-based therapeutics to treat inflammatory diseasesFiscal year 2025 · $50KNIH RePORTER 3R44GM144019-03S1 · fetched Nov 12, 2026
- Synthesis of the library of heparan sulfate hexasaccharide mimeticsFiscal year 2025 · $1.1MNIH RePORTER 5R44GM145004-03 · fetched Nov 12, 2026
- Development of anticoagulant sulfated glycansFiscal year 2025 · $1.1MNIH RePORTER 5R44GM148100-03 · fetched Nov 12, 2026
- Development of dekaparin to replace animal-sourced heparinFiscal year 2025 · $991.2KNIH RePORTER 5R44HL139187-05 · fetched Nov 12, 2026
- Development of dekaparin to replace animal-sourced heparinFiscal year 2024 · $747.3KNIH RePORTER 2R44HL139187-04 · fetched Nov 12, 2026
- National I-Corps: Development of synthetic heparin to protect liver graft from ischemia reperfusion injury during transplantationFiscal year 2024 · $55KNIH RePORTER 3R41CA285005-01S1 · fetched Nov 12, 2026
- Synthesis of the library of heparan sulfate hexasaccharide mimeticsFiscal year 2024 · $1.1MNIH RePORTER 4R44GM145004-02 · fetched Nov 12, 2026
- Development of anticoagulant sulfated glycansFiscal year 2024 · $1.1MNIH RePORTER 4R44GM148100-02 · fetched Nov 12, 2026
- Development of heparan sulfate-based therapeutics to treat inflammatory diseasesFiscal year 2024 · $1.5MNIH RePORTER 5R44GM144019-03 · fetched Nov 12, 2026